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Objectives: To explore the notion of mutation-centric pharmacogenomic relation extraction and to eval-
uate our approach against reference pharmacogenomic relations.
Methods: From a corpus of MEDLINE abstracts relevant to genetic variation, we identify co-occurrences
between drug mentions extracted using MetaMap and RxNorm, and genetic variants extracted by
EMU. The recall of our approach is evaluated against reference relations curated manually in PharmGKB.
We also reviewed a random sample of 180 relations in order to evaluate its precision.
Results: One crucial aspect of our strategy is the use of biological knowledge for identifying speciﬁc
genetic variants in text, not simply gene mentions. On the 104 reference abstracts from PharmGKB,
the recall of our mutation-centric approach is 33–46%. Applied to 282,000 abstracts from MEDLINE,
our approach identiﬁes pharmacogenomic relations in 4534 abstracts, with a precision of 65%.
Conclusions: Compared to a relation-centric approach, our mutation-centric approach shows similar
recall, but slightly lower precision. We show that both approaches have limited overlap in their results,
but are complementary and can be used in combination. Rather than a solution for the automatic cura-
tion of pharmacogenomic knowledge, we see these high-throughput approaches as tools to assist biocu-
rators in the identiﬁcation of pharmacogenomic relations of interest from the published literature. This
investigation also identiﬁed three challenging aspects of the extraction of pharmacogenomic relations,
namely processing full-text articles, sequence validation of DNA variants and resolution of genetic vari-
ants to reference databases, such as dbSNP.
Published by Elsevier Inc.1. Introduction
One aspect of personalized medicine is better adaptation of
therapeutic drugs to the speciﬁc situation of a given patient, part
of which is determined by his or her unique genetic make-up.
Pharmacogenomics attempts to assess the inﬂuence of genetic var-
iation on drug response [10,28]. One poster child of pharmacoge-
nomics is the drug warfarin, an anticoagulant widely prescribed
for the prophylaxis and treatment of thromboembolic phenomena
in patients with deep vein thrombosis and atrial ﬁbrillation. War-
farin has a narrow therapeutic index, that is, small changes in the
dose result in important variations of the therapeutic effect. For
an anticoagulant, this means either insufﬁcient anticoagulation
and risk of thrombosis if the dose is too low, or excessive anticoag-
ulation and increased hemorrhagic risk if the dose is too high. Since
a large fraction of the therapeutic effect ofwarfarin is dependent on
genetic variation, it has been shown that testing patients for vari-
ations in speciﬁc genes can help determine the initial dose andInc.
of Medicine, 8600 Rockville
20894, USA. Fax: +1 301 480
er).enhance clinical outcomes [18]. More speciﬁcally, CYP2C9 and
VKORC1 genotype information can be integrated into algorithms
used for the determination of the maintenance dose of warfarin,
outperforming traditional algorithms (not using genotype informa-
tion), especially for patients requiring low or high doses [18].
Examples of allelic variants include the point mutation G3673A,
associated with response to a lower dose ofwarfarin [25]. The exact
place of CYP2C9 and VKORC1 genotyping in anticoagulation with
warfarin has been subject to debate [11]. However, recent studies
have demonstrated lower risk of hospitalization for hemorrhage
or thromboembolism in patients for which genetic information
had been determined [9]. While genetic information is not yet used
routinely with warfarin prescription, CYP2C9 and VKORC1 geno-
typing is widely available, and the Food and Drug Administration’s
standard product label for warfarin now discusses the practical
inﬂuence of allelic variation on the dose needed by speciﬁc patient
groups.
The biomedical literature is the primary vehicle for reporting
the association between gene variants and drugs. Pharmacoge-
nomic information is generally extracted from text and curated
manually in order to create reference knowledge bases, such as
PharmGKB [16,19]. Information extraction can also be automated
using natural language processing (NLP) tools [12]. However, text
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generally show limited precision [13]. Our goal here is to leverage
biological knowledge to increase the performance of information
extraction methods. In previous work [24], we exploited the bio-
medical literature using a method based mainly on co-occurrences,
with limited success. We now apply the lessons learned from this
preliminary work to improve our methods. The singlemost impor-
tant element is the identiﬁcation of allelic variants. Towards this
end, we introduce EMU [8], an extractor of mutations, to comple-
ment our original approach.
The objectives of this study are both to explore the notion of
mutation-centric pharmacogenomic relation extraction and to
evaluate our approach against reference pharmacogenomic rela-
tions. Additionally, we compare our approach to a relation-centric
approach and we outline the potential of our approach to support
the curation of pharmacogenomic relations.2. Background
2.1. PharmGKB
PharmGKB [19] aims to collect, gather and communicate the
knowledge about the impact of human genetic variations on drug
response. PharmGKB curation efforts are concentrated on a small
set of very important pharmacogenes (referred to as VIP genes),
for which a comprehensive domain expert annotation is provided.
For these genes, the speciﬁc genetic variants are identiﬁed, along
with related drugs and phenotypes. The articles from which the
information was extracted are listed as evidence. It must be noted,
however, that pharmacogenomic knowledge in PharmGKB is cu-
rated from a limited set of high-quality journals and for a small
number of drugs and genes of particular interest, and is therefore
not comprehensive.2.2. Approaches to extracting pharmacogenomic information
Extracting pharmacogenomic information from the biomedical
literature, i.e., information about drugs, phenotypes, gene variants
and their interrelations, can be seen as a speciﬁc task in the broad-
er discipline of text mining (see [1,29] for a review of text mining).
A recent review article provides a rich description of the state of
the art [13] and we will therefore keep our own review of related
work to a minimum.
As summarized in [13], approaches to extracting pharmacoge-
nomic relations share many features. Common to all approaches
is the identiﬁcation of named entities of interest (drugs, diseases,
genes and their variants) from the biomedical literature, relying
on dictionaries, rules or machine learning techniques. Analogously,
the identiﬁcation of the relations among these entities generally
relies on the presence of these entities within a given span of text,
i.e., co-occurrence. Additional cues are used to avoid false positive
relations, including statistical cues (e.g., frequency of co-occur-
rence) and linguistic cues (e.g., syntactic dependencies among enti-
ties). Models of such relations can also be identiﬁed through
machine learning approaches.
Some of the systems developed recently were presented at the
workshop on ‘‘Mining the pharmacogenomics literature’’ organized
at the Paciﬁc Symposium on Biocomputing 2011. Interestingly, the
following systems all leverage dependency graphs, i.e., graphs rep-
resenting the syntactic structure of sentences, to extract pharmac-
ogenomic relations, and can be thought of as ‘‘relation-centric
approaches’’. Initially developed for event extraction in the BioNLP
Shared Task, JReX was adapted to gene-drug relation extraction [5].
Analogously, the OntoGene Relation Miner developed for extract-
ing protein–protein interactions was extended to support theextraction of pharmacogenomic relations [26]. Not surprisingly,
the largest pharmacogenomic text mining effort was done by the
researchers associated with PharmGKB curation at Stanford Uni-
versity [7]. Since we compare our results to theirs, their approach
is described later in Section 5.
Although not speciﬁc to the extraction of pharmacogenomic
relations, some recent work in biomedical information extraction
is relevant to our investigation. OpenDMAP, the Open source Direct
Memory Access Parser, developed at the University of Colorado is
an ontology-driven system that achieves high precision [17]. The
use of biological knowledge has been shown to increase the perfor-
mance of information extraction systems [20]. In particular, the
use of nucleotide and amino acid sequences, leveraged by EMU
for extracting mutations from text, has also been identiﬁed as a
key element for the normalization of ambiguous gene names
among species in the GNAT system [15].
The speciﬁc contribution of this work is not the development of
a new method, but rather the combination of existing tools and
techniques (MetaMap, RxNorm ﬁltering, EMU) into a novel strat-
egy for identifying pharmacogenomic relations. While based on
co-occurrence between genes and drugs, our strategy is character-
ized by the use of biological knowledge for identifying speciﬁc ge-
netic variants in text. Our approach can therefore be termed a
‘‘mutation-centric approach’’.3. Datasets and methods
Our approach to extracting pharmacogenomic information from
text takes advantage of biological knowledge to increase the preci-
sion of the simple co-occurrence approach. Drug mentions and ge-
netic variants are identiﬁed in MEDLINE abstracts in order to
establish a list of harticle, drug, genetic varianti relations. We pres-
ent an example illustrating the identiﬁcation of point mutations
and drug mentions. The applicability of our high-throughput meth-
od is veriﬁed on a large set of MEDLINE abstracts relevant to genet-
ic variation. Finally, our results are evaluated against reference
relations curated manually in PharmGKB.3.1. Identifying drugs
We identify drugs in text by using a generic biomedical entity
recognition system, MetaMap, and restricting its output with the
drug-speciﬁc resource RxNorm.3.1.1. MetaMap
MetaMap [2] is a medical concept recognizer developed by the
National Library of Medicine. MetaMap annotates biomedical text
with concepts from the Uniﬁed Medical Language System (UMLS)
[3]. In practice, MetaMap associates a UMLS concept unique iden-
tiﬁer with any medical concept recognized in the text. Moreover, it
is important to map drugs to a reference terminology in order to
facilitate comparisons across resources. Therefore, we ﬁlter and
normalize the concepts extracted by MetaMap using a drug-spe-
ciﬁc resource, RxNorm.3.1.2. RxNorm
RxNorm [23] is a standardized nomenclature for clinical drug
entities developed by the National Library of Medicine. RxNorm
is one of a suite of designated standards for use in U.S. Federal Gov-
ernment systems for the electronic exchange of clinical health
information. The RxNorm model distinguishes between various
types of drug entities (e.g., ingredient, precise ingredient, brand
name) and asserts relations among these types, making it possible
to navigate among them. RxNorm is integrated in the UMLS. In
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normalization steps.3.1.2.1. Filtering. From all the biomedical concepts extracted by
MetaMap, only those concepts present in RxNorm as drug ingredi-
ents are selected, ensuring that only drug concepts are retained.
Molecules such as amino acids, simple sugars (e.g., glucose) and
inorganic elements (e.g., calcium) are listed as ingredients in
RxNorm. However, when mentioned in the biomedical literature,
these molecules rarely refer to clinical drugs. Therefore, we elimi-
nate them from the list of drugs identiﬁed by RxNorm.3.1.2.2. Normalization. Variation in drug names is generally cap-
tured by the UMLS, where synonymous names are associated with
the same concept. In contrast, salt and non-salt ingredients (ator-
vastatin and atorvastatin calcium) denote different entities in the
UMLS. For the purpose of relating drugs to genetic variants, it is
preferable to ignore such differences. We leverage RxNorm rela-
tions to aggregate drug entities at the appropriate ingredient level.3.2. Identifying genetic variants
We identify point mutations in text and attempt to resolve
them to reference single nucleotide polymorphisms (SNPs) in
dbSNP [21,27] whenever possible. While methods such as Muta-
tionFinder [6] have been developed to extract mutational informa-
tion from biomedical text with high precision, these methods lack
the mutation-gene associations required here in order to relate
drugs to speciﬁc genetic variants. In prior work, we developed
EMU [8] (Extractor of Mutations) to identify point mutations and
their associated genes in biomedical text. (A detailed example of
identiﬁcation of a point mutation by EMU is presented in the next
section.) One original feature of EMU compared to other such tools
is to leverage biological information for the validation of the muta-
tions extracted against reference sequences. More speciﬁcally, for
candidate mutations identiﬁed in abstracts with regular expres-
sions speciﬁcally crafted for capturing the many ways in which
mutations are expressed in text, the protein products of the corre-
sponding genes are checked for the possible existence of a muta-
tion at the location indicated (i.e., we verify that the wild type
amino acid recorded in the given mutation corresponds to the
actual amino acid in the speciﬁed protein sequence position).
Finally, EMU attempts to resolve each variant to an identiﬁer (rsid)
from the reference database of SNPs, dbSNP. Of note, while EMU is
designed to identify mentions of mutations referring to either
nucleotide or amino acid sequences, only the protein mutations
can be validated against reference sequences.
In our mutation-centric approach, speciﬁc genetic variants, not
only gene mentions, are identiﬁed in text. Moreover, whenever
possible, the genetic variants are validated against reference se-
quences and resolved to the reference database dbSNP.
In summary, after applying the drug and gene variant identiﬁca-
tion methods to a set of MEDLINE abstracts, we obtain a smaller set
of abstracts in which we have identiﬁed pharmacogenomic rela-
tions of the form harticle, drug, genetic varianti.3.3. Extended example
In order to illustrate how pharmacogenomic relations are iden-
tiﬁed in text, we use the following text fragment from the abstract
of a PubMed article (PMID 12492608) [14]: A noncoding single
nucleotide polymorphism (SNP) in exon 26 3435C>T of the highly
polymorphic MDR1 gene has been demonstrated to alter digoxin
absorption [. . .].3.3.1. Genetic variant
In this sentence, EMU identiﬁed a DNA mutation. ‘‘3435C>T’’
denotes a single nucleotide polymorphism (SNP) in which the
nucleotide C is substituted by T in position 3435 on the reference
sequence NM_000927.3 (chromosomal position 87138645 on
chromosome 7), corresponding to the human gene ABCB1 (for
which MDR1 is a synonym). This SNP can be resolved to
rs1045642 in the reference database of SNPs, dbSNP, which vali-
dates the mutation identiﬁed by EMU. (Since EMU does not sup-
port sequence validation for DNA mutations, resolution to dbSNP
of the genetic variant identiﬁed by EMU was performed manually
in this case).
3.3.2. Drug
MetaMap identiﬁed the drug digoxin in the sentence, which it
mapped to the UMLS concept C0012265. Since this drug is listed
as an ingredient in RxNorm (RxCUI 3407), it was selected as a valid
drug.
Overall, our approach identiﬁed the relation h3435C>T/
rs1045642, digoxin(RxCUI:3407)i from article PMID:12492608 as
a potential pharmacogenomic relation. Of note, this relation is also
among the gene variants curated in PharmGKB (ABCB1:3435T>C).
3.4. Application to a large set of MEDLINE abstracts
In order to restrict the large MEDLINE corpus (over 20 M
citations) to a manageable dataset, we ﬁrst use the PubMed search
engine to select those abstracts in which pharmacogenomic infor-
mation is most likely to be identiﬁed. In prior work, we determined
that two Medical Subject Headings (MeSH) descriptors, ‘‘Mutation’’
OR ‘‘Polymorphism, Genetic’’, were used most frequently as index-
ing terms in articles referenced in the PharmGKB VIP (very impor-
tant pharmacogenes) dataset. Here, we further constrain the search
by restricting it to articles published since 2000 (earlier abstracts
are less likely to contain genomic information), in English, and
for which an abstract is available. This PubMed search was per-
formed in January 2011 and yielded 281,947 abstracts identiﬁed
by their PubMed identiﬁer (PMID). We also considered processing
full-text articles, but despite the growth of PubMed Central over
the past few years, a relatively small proportion of articles is pub-
licly accessible and amenable to processing by our tools. (We come
back to full-text processing in Section 5). Each abstract in this set
was submitted to the drug and gene variant identiﬁcation pro-
cesses presented above.
3.5. Evaluation
3.5.1. Recall
For evaluation purposes, we use a reference dataset of 104 arti-
cles corresponding to the PharmGKB VIP (very important pharmac-
ogenes) dataset. We compare the harticle, drug, genetic varianti
relations we extracted to similar reference relations curated man-
ually in PharmGKB. Here we evaluate recall, i.e., the ability of our
methods to identify these relations from a set of reference docu-
ments. In PharmGKB, we concentrate on those hdrug, genetic vari-
anti relations that have undergone in-depth curation (‘‘VIP
annotations’’). For example, for the drug warfarin, VIP annotations
are provided only for the gene VKORC1, for which three variants
are listed (G3673A, C6484T, G9041A). For each variant, MEDLINE
abstracts are cited in reference (e.g., PMID: 16270629 for all 3 vari-
ants). In practice, PharmGKB provides hdrug, allelic variant, articlei
relations. For the identiﬁcation of allelic variants, we use the iden-
tiﬁer from dbSNP (rsid) listed in PharmGKB. Drugs listed in Phar-
mGKB are normalized with RxNorm, as was done for the drugs
extracted from the literature.
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Precision cannot be evaluated with this reference dataset, be-
cause PharmGKB is not exhaustive (i.e., other valid hdrug, genetic
varianti relations may be present in the reference set of PharmGKB
abstracts, but not curated). In order to estimate precision, i.e., the
ability of our approach to identify only pharmacogenomic rela-
tions, we selected a random sample of 180 relations extracted from
the large set of MEDLINE abstract by our high-throughput ap-
proach. Each relation extracted was reviewed independently by
two authors with expertise in medicine and bioinformatics. All dif-
ferences were reconciled by consensus. We considered false posi-
tives those relations where the mutation does not correspond to
the gene (e.g., non-human variants) and where the drug is not
mentioned in a clinical context (e.g., folate used as a reagent).
4. Results
The contribution of each step of the mutation-centric approach
applied to a large set of MEDLINE abstracts is brieﬂy presented, fol-
lowed by the evaluation of our approach in terms of recall and
precision.
4.1. Application to a large set of MEDLINE abstracts
The number of abstracts selected at each step of our approach is
shown in Fig. 1. The initial PubMed search yielded 281,947 ab-
stracts. Of these, 35,926 (12.7%) were identiﬁed by EMU as contain-
ing mention of some point mutation with its associated gene. A
drug was identiﬁed by MetaMap and RxNorm in 63,027 abstracts
(22.3%), for a total of 1970 unique drugs. (The number of unique
mutations is not known as the mutations have not been normal-
ized.) Overall, we found a total of 12,590 hdrug, genetic varianti
relations in 4534 abstracts.
4.2. Evaluation
4.2.1. Recall
The proportion of reference abstracts identiﬁed as relevant by
our approach measures the recall of our approach. Of the 104 ref-
erence abstracts, 34 (33%) were identiﬁed by our approach as con-
taining mention of both a drug and a mutation. Recall can also be
measured for the hdrug, genetic varianti relations from the refer-
ence documents, using an rsid from dbSNP as genetic variant iden-
tiﬁer. Of such 441 reference relations, 57 (13%) were identiﬁed by
our approach (with automatic or manual resolution to dbSNP). TheMutation-centric approach
MEDLINE subset
Abstracts
with drug(s)
PGxsubset
Identify drugs
(MetaMap/RxNorm)
Identify genetic
variants (EMU)
282k abstracts
63k abstracts
1970 unique drugs
4534 abstracts
12,590 relations
Abstracts with
genetic variant(s)
Intersection
36k abstracts
Precision: 65%
Fig. 1. Mutation-centric approach applied to a large set of MEDLINE abstracts.441 reference relations correspond to 85 unique drugs, 29 unique
genetic variants and 420 unique hdrug, genetic varianti relations. A
failure analysis is presented in Section 5.
4.2.2. Precision
Of the 180 hdrug, genetic varianti relations randomly selected
from the 12,590 relations extracted from the large set of MEDLINE
abstracts, 65% have been identiﬁed as true positives by manual
review.5. Discussion
We ﬁrst point out salient elements of the results and discuss
their signiﬁcance, before comparing our approach to the relation-
centric approach developed at Stanford. Then we review some of
the remaining challenges in extracting pharmacogenomic rela-
tions. Finally we present the application of this work to the prior-
itization of pharmacogenomic relations for biocurators.
5.1. Findings and signiﬁcance
With a recall of 33% for the abstracts and 13% for the hdrug, ge-
netic varianti relations in comparison to the reference abstracts cu-
rated in PharmGKB, the performance of our approach seems
inadequate. We performed an analysis and identiﬁed the following
reasons for failure, illustrated in Fig. 2.
Uponmanual review of the 104 abstracts from the reference set,
we determined that a genetic variant was explicitly mentioned in
the abstract (or title) in only 46 cases (44%). In other words, in over
half of the cases, biocurators have relied on information from full-
text articles or external sources for extracting pharmacogenomic
relations. (Issues in processing full-text articles are discussed
later.)
From the 46 abstracts whose abstracts contain explicit men-
tions of genetic variants, EMU failed to identify the mutation in
12 cases. For example, from the text fragment the Gly49Arg389/
Ser49Gly389 diplotype in article PMID:12844134, EMU missed the
two mutations: Gly49Ser (rs1801252) and Arg389Gly (rs1801253)
in the human gene ADRB1. Although EMU handles concatenated
mutations, here the concatenation pattern is unusual and ambigu-
ous with more common patterns (confusion with Gly49Arg and
Ser49Gly).
The recall observed on the reference dataset arguably corre-
sponds to the lower bound of the performance of our method.
The reference dataset contains an uncharacteristically large pro-
portion of older abstracts (30 of the 104 abstracts published beforeall
reference
articles
no explicit
mention
of genetic
variant in
abstract
explicit
mention
of genetic
variant in
abstract
identified
by EMU
not identified
by EMU
104
12
5846
34
Fig. 2. Failure analysis: Number of abstracts from the reference dataset for which
an explicit mention of genetic variant is found in the abstract and identiﬁed by
EMU.
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be available and where genetic variation is less likely to be ex-
pressed in a standard manner. When measured on the subset of
the reference abstracts published in 2000 or after, the performance
of our method increases signiﬁcantly. In fact 34 of the 74 recent ab-
stracts are identiﬁed as relevant, increasing the recall to 46% (from
33%).
5.2. Comparison to Stanford’s relation-centric approach
5.2.1. The relation-centric approach
The Stanford group applied a relation-centric approach to
extracting pharmacogenomic relations from MEDLINE [7]. They
processed the whole MEDLINE dataset, parsed 87 million sentences
in order to identify syntactic dependencies between two entities,
one representing gene variation (e.g., VKORC1 polymorphisms) and
the other related to a drug (e.g., warfarin dose) or phenotype (e.g.,
thrombophlebitis). They used a simple lexicon-based method for
identifying genes, drugs and phenotypes in text, but a linguisti-
cally-motivated method for identifying associations between enti-
ties in text from the syntactic structure of the sentence. They
created an ontology to organize and normalize the types of entities
and relationships encountered. However, no attempt was made to
systematically identify gene variants or to resolve them to refer-
ence databases. They extracted over 41,000 hgene variation entity,
relationship, drug/phenotype entityi relations, with a precision of
88% (evaluated on a sample of 220 relations). The Stanford group
shared with us the list of abstracts fromwhich a pharmacogenomic
relation had been identiﬁed, but not the relations themselves. Ap-
plied to our subset of 282,000 MEDLINE abstracts, the Stanford ap-
proach identiﬁed 2764 abstracts containing pharmacogenomic
relations.
5.2.2. Contrasting the two approaches
The identiﬁcation of the relation between genetic variants and
drugs differs in two respects between the two approaches, namely
in scope and extraction method. The mention of a genetic variant is
identiﬁed directly in the mutation-centric approach, while the
relation-centric approach ﬁrst detects a gene name and then the
indication of variation through a modiﬁer (e.g., VKORC1 SNP). Drug
identiﬁcation relies on dictionaries in both cases, but the relation-
centric approach identiﬁes not only drugs, but also phenotypes re-
lated to genetic variants. Finally, the relation is approximated by
simple co-occurrence within the abstract in the mutation-centric
approach, while it is conﬁned to a sentence and derived from its
syntactic structure in the relation-centric approach.
5.2.3. Comparison
The comparison assesses whether a given abstract selected as
the source of pharmacogenomic relations by one approach is also
selected by the other. The relations themselves are not compared,
because only the set of abstracts in which relations were identiﬁed
by Stanford was made available to us.
5.2.3.1. Both approaches show limited recall. Of the 104 abstracts of
the reference dataset, 34 (33%) were identiﬁed by our mutation-
centric approach, while 36 (35%) were identiﬁed by the relation-
centric approach. In both cases, recall is inadequate to support
automatic biocuration. The advantage of both approaches, how-
ever, is that they are fully automated and can be used to scan
the biomedical literature systematically.
5.2.3.2. Both approaches show state-of-the-art precision. In the
absence of a gold standard for pharmacologic relations, both
groups relied on manual review of a limited set of relations to eval-
uate the precision of their approach. Not surprisingly, more falsepositives are identiﬁed by our co-occurrence-based approach than
by Stanford’s approach where linguistic cues are required to sup-
port the relation. However, with a precision of 65% for the muta-
tion-centric approach and 88% for the relation-centric approach,
the performance of both approaches reﬂects the state of the art
in relation extraction.
5.2.3.3. Complementarity between the two approaches. Of the 104
abstracts of the reference dataset, eight abstracts (7.7%) are found
by both approaches. The overlap between the two approaches is
also limited on the set of 282,000 MEDLINE abstracts, where only
224 abstracts are identiﬁed by both methods, representing 4.9%
of the abstracts identiﬁed by the mutation-centric approach and
8.1% of the abstracts identiﬁed by the relation-centric approach.
Given the differences between the two approaches, we did not
expect a large overlap between the two result sets. However, the
proportion of abstracts identiﬁed by both approaches is extremely
limited. Since both approaches have reasonable precision, the two
approaches are complementary and can be used jointly to help
identify pharmacogenomic relations from the biomedical litera-
ture. For example, our mutation-centric approach identiﬁed 34 of
the 104 reference abstracts, while Stanford’s relation-centric ap-
proach identiﬁed 36, with an overlap of eight. Therefore the two
approaches identiﬁed 62 distinct abstracts and the recall of the
combined approaches on the reference abstracts is 60%, i.e., signif-
icantly higher than the recall of 35% obtained by each approach ta-
ken in isolation.
5.3. Remaining challenges
Processing full-text articles, sequence validation of DNA vari-
ants and resolution of genetic variants to reference databases are
three aspects of the extraction of pharmacogenomic relations that
remain particularly challenging.
5.3.1. Processing full-text articles
As mentioned earlier, we chose to process abstracts rather than
full-text articles in this study, mainly because a majority of full-
text articles are still not available in public access repositories,
such as PubMed Central [22]. In fact, of the 104 articles in the ref-
erence dataset, only 33 (32%) are available there. Moreover, when
available, full-text articles often need to be converted from PDF
format, which is suboptimal as it may result in loss of the docu-
ment structure.
Using our mutation-centric approach, we processed the 33 arti-
cles available in full text downloaded from PubMed Central. While
11 of these 33 articles (33%) had already been identiﬁed as a source
of pharmacogenomic relations based on the abstract alone, ﬁve
additional articles were identiﬁed when processing the full text,
increasing recall to 48%. This limited experiment suggests that
two thirds of the relevant articles can be identiﬁed based solely
on the abstracts.
5.3.2. Sequence validation of DNA variants
EMU failed to provide sequence validation for 26 of the 34
mutations it identiﬁed from the reference dataset, because these
mutations were described in reference to nucleotide sequences,
rather than amino acid sequences. While we were able to conﬁrm
the validity of these 26 mutations manually using dbSNP as a ref-
erence, automatic sequence validation remains challenging for
DNA mutations, because comparing nucleotide sequences (combi-
nations of four nucleotides) is likely to yield incorrect associations
more frequently than when comparing amino acid sequences
(combinations of 20 amino acids). Overall, sequence validation
could be obtained for less than one third of the mutations detected
by EMU. While we showed in earlier work that sequence validation
840 B. Rance et al. / Journal of Biomedical Informatics 45 (2012) 835–841signiﬁcantly contributed to the precision of EMU [8], such require-
ment also signiﬁcantly decreases recall. In practice, sequence vali-
dation was not required as part of the identiﬁcation of genetic
variants in this study.
5.3.3. Resolution of genetic variants to reference databases
References databases of point mutations, such as dbSNP, are
still incomplete, i.e., not all genetic variants described in the
biomedical literature have been recorded in dbSNP. Therefore, only
a fraction of the genetic variants identiﬁed by EMU can be resolved
into an entry in dbSNP and associated with an rsid. Examples
of mutations automatically resolved to dbSNP by EMU include
Ala893Ser identiﬁed in gene MDR1 from the article PMID:
11503014 and resolved to the variant rs2032582. In contrast,
EMU failed to resolve the DNA mutation C3435T in the same gene
from PMID:10716719 (resolved manually to rs1045642). However,
we showed that failure by EMU to resolve a given mutation to
dbSNP (for a nucleotide or amino acid sequence) was not indicative
of invalid mutation identiﬁcation.
5.4. Application to support the curation of pharmacogenomic relations
Our approach to identifying pharmacogenomic relations was
never envisioned as a solution to automatic curation of pharmac-
ogenomic knowledge. The identiﬁcation of pharmacogenomic rela-
tions is only one element of the development of a resource, such as
PharmGKB, as biocurators generally collect additional information,
including allele frequency and odds-ratios, in order to precisely
characterize the inﬂuence of a given genetic variant on drug effect.
However, we argue that high-throughput approaches, such as ours,
can help support and prioritize biocuration efforts by providing en-
hanced information retrieval and quantiﬁcation of the frequency of
the pharmacogenomic relations.
5.4.1. Enhanced information retrieval
Biocuration efforts are limited by the resources of teams, such
as PharmGKB. Therefore, biocurators typically restrict their effort
to a small number of articles from selected journals and provide
in-depth curation only for a limited set of genetic variants. In con-
trast, high-throughput approaches including our mutation-centric
approach and Stanford’s relation-centric approach can be used
for scanning the literature systematically and regularly. Even if
their recall is limited, the precision of these approaches is sufﬁcient
to make useful recommendations to biocurators. Recall can be in-
creased by combining several complementary high-throughput ap-
proaches and by processing full-text articles when available. Gains
in precision can be obtained through additional ﬁltering (e.g., on
journal, publication date and MeSH indexing). Moreover, our
mutation-centric approach would help biocurators identify all ge-
netic variants mentioned in the literature for a drug of interest.
5.4.2. Quantiﬁcation of the frequency of the pharmacogenomic
relations
One issue for biocurators is to prioritize the drugs and genetic
variants on which to concentrate their efforts. High-throughput
approaches can help perform automatic ‘‘surveillance’’ of the drugs
and genetic variants discussed in the literature, as well as quantify
the frequency of the pharmacogenomic relations for certain drugs
or drug classes. For example, the top 15 drugs we identiﬁed in
pharmacogenomic relations extracted from the 290,000 MEDLINE
abstracts, participate in 3197 pharmacogenomic relations. Among
these 15 drugs, three tyrosine kinase inhibitors, geﬁtinib, imatinib
and erlotinib, account for 18% of the 3197 relations (and 4.6% of all
relations). This example illustrates how drug classes of interest can
easily be screened for their association with genetic variants and
possibly given a higher priority in the curation process.6. Conclusion
Several approaches to identifying pharmacogenomic relations
from the biomedical literature have been investigated recently. In
contrast to methods relying on sophisticated NLP techniques
(e.g., Stanford’s relation-centric approaches), we propose a muta-
tion-centric approach in which speciﬁc genetic variants, not only
gene mentions, are identiﬁed in text and validated against refer-
ence sequences whenever possible. When evaluated against a ref-
erence set of abstracts from PharmGKB, our approach exhibited a
recall of 33–46%, which is similar to the performance of relation-
centric approaches. The precision of our approach is 65%. More-
over, we showed that mutation-centric and relation-centric ap-
proaches are complementary. This investigation identiﬁed three
challenging aspects of the extraction of pharmacogenomic rela-
tions, namely processing full-text articles, sequence validation of
DNA variants and resolution of genetic variants to reference dat-
abases, such as dbSNP. Given the limited performance of automatic
approaches to identifying pharmacogenomic relations, the princi-
pal interest of these methods is their ability to process vast
amounts of biomedical text automatically. Rather than a solution
for the automatic curation of pharmacogenomic knowledge, we
see these high-throughput approaches as tools to assist biocurators
in the identiﬁcation of pharmacogenomic relations of interest from
the published literature.
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